Comparative Pharmacology
Head-to-head clinical analysis: CROMOPTIC versus NEDOCROMIL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROMOPTIC versus NEDOCROMIL SODIUM.
CROMOPTIC vs NEDOCROMIL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer that inhibits the release of histamine and other inflammatory mediators from mast cells. Also inhibits eosinophil chemotaxis and activation.
Nedocromil sodium is a mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from mast cells and other inflammatory cells. It also reduces sensory nerve activation and inhibits eosinophil chemotaxis.
1-2 drops in each eye 4 times daily for conjunctivitis; 1 drop in each eye 2-4 times daily for allergic conjunctivitis prophylaxis.
2 inhalations (2 mg per inhalation) four times daily via metered-dose inhaler, or 2 inhalations (4 mg per inhalation) twice daily via dry powder inhaler.
None Documented
None Documented
1.3 hours (terminal elimination half-life); clinically, due to rapid elimination, dosing is required 4 times daily for sustained effect.
Terminal elimination half-life is approximately 2 hours; clinically, this supports twice-daily dosing for sustained effect.
Primarily renal excretion of unchanged drug (approximately 70% within 24 hours); the remainder is excreted in feces via biliary elimination (approximately 30%).
Primarily renal excretion of unchanged drug; approximately 70% excreted in urine and 30% in feces via biliary elimination.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer